Open Access. Powered by Scholars. Published by Universities.®
- Institution
- Keyword
-
- Cardiovascular epidemiology (2)
- Internal medicine and geriatrics (2)
- 80 and over (1)
- Adult (1)
- Aged (1)
-
- Antineoplastic Combined Chemotherapy Protocols (1)
- Carcinoma (1)
- Carcinoma, Small Cell (1)
- Coronary heart disease (1)
- Cyclophosphamide (1)
- Diabetes (1)
- Doxorubicin (1)
- Education and public health (1)
- Epirubicin (1)
- Female (1)
- Humans (1)
- Local (1)
- Lung Neoplasms (1)
- Male (1)
- Middle Aged (1)
- Mortality (1)
- Neoplasm Recurrence (1)
- Neoplasm Recurrence, Local (1)
- Obesity and diabetes epidemiology (1)
- Rastreamento (1)
- Remission Induction (1)
- Small Cell (1)
- Survival Rate (1)
- Treatment Failure (1)
- Vincristine (1)
- Publication
- File Type
Articles 1 - 5 of 5
Full-Text Articles in Epidemiology
Using Treatment Interruptions To Palliate The Toxicity From Concurrent Chemoradiation For Limited Small Cell Lung Cancer Decreases Survival And Disease Control, Gregory Videtic, Karen Fung, Anna Tomiak, Larry Stitt, A. Dar, Pauline Truong, Edward Yu, Mark Vincent, Walter Kocha
Using Treatment Interruptions To Palliate The Toxicity From Concurrent Chemoradiation For Limited Small Cell Lung Cancer Decreases Survival And Disease Control, Gregory Videtic, Karen Fung, Anna Tomiak, Larry Stitt, A. Dar, Pauline Truong, Edward Yu, Mark Vincent, Walter Kocha
Edward Yu
BACKGROUND AND PURPOSE: We analyzed the impact on survival outcomes of treatment interruptions due to toxicity arising during the concurrent phase of chemotherapy/radiotherapy (ChT/RT) for our limited-stage small-cell cancer (LSCLC) population over the past 10 years. MATERIALS AND METHODS: From 1989 to 1999, 215 patients received treatment for LSCLC, consisting of six cycles of alternating cyclophosphamide/doxorubicin or epirubicin/vincristine (CAV; CEV) and etoposide/cisplatin (EP). Thoracic RT was started with EP at either the second or third cycle (85% of patients). RT dose was either 40 Gy in 15 fractions over 3 weeks or 50 Gy in 25 fractions over 5 weeks, …
Diabetes And All-Cause And Coronary Heart Disease Mortality Among Us Male Physicians, Paulo A. Lotufo, Joann E. Manson
Diabetes And All-Cause And Coronary Heart Disease Mortality Among Us Male Physicians, Paulo A. Lotufo, Joann E. Manson
Paulo A Lotufo
Background: While diabetes has long been associated
with increased risk of coronary heart disease (CHD), the
magnitude of risk of diabetes-related CHD is uncertain.
Objective: To evaluate the impact of diabetes and prior
CHD on all-cause and CHD mortality.
Methods: In a prospective cohort study of 91 285 US
male physicians aged 40 to 84 years, participants were
divided into 4 groups: (1) a reference group of 82 247
men free of both diabetes and CHD (previous myocardial
infarction and/or angina) at baseline, (2) 2317 men
with a history of diabetes but not CHD, (3) 5906 men
with a history …
Coffee, Samba, Football And Social Inequalities: Some Lessons From Mortality In Brazil, Paulo A. Lotufo
Coffee, Samba, Football And Social Inequalities: Some Lessons From Mortality In Brazil, Paulo A. Lotufo
Paulo A Lotufo
No abstract provided.
O Nosso Amigo Esfigmomanômetro [Portuguese], Paulo A. Lotufo
O Nosso Amigo Esfigmomanômetro [Portuguese], Paulo A. Lotufo
Paulo A Lotufo
No abstract provided.
O Exame Físico Com Finalidade De Prevenção: Estudos De Base Populacional. [Portuguese], Paulo A. Lotufo
O Exame Físico Com Finalidade De Prevenção: Estudos De Base Populacional. [Portuguese], Paulo A. Lotufo
Paulo A Lotufo
No abstract provided.